FDA approves Celltrion Tevas Rituxan biosimilar but with a narrow label

FDA approves Celltrion, Teva’s Rituxan biosimilar, but with a narrow label

The agency approved Truxima for three lymphoma indications, whereas European regulators approved it last year for all the same indications as the reference product, Roche’s Rituxan.

More From BioPortfolio on "FDA approves Celltrion, Teva’s Rituxan biosimilar, but with a narrow label"